142 related articles for article (PubMed ID: 19968781)
21. CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery.
Yang XR; Xu Y; Yu B; Zhou J; Li JC; Qiu SJ; Shi YH; Wang XY; Dai Z; Shi GM; Wu B; Wu LM; Yang GH; Zhang BH; Qin WX; Fan J
Clin Cancer Res; 2009 Sep; 15(17):5518-27. PubMed ID: 19706825
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of high-mobility group box 2 is associated with tumor aggressiveness and prognosis of hepatocellular carcinoma.
Kwon JH; Kim J; Park JY; Hong SM; Park CW; Hong SJ; Park SY; Choi YJ; Do IG; Joh JW; Kim DS; Choi KY
Clin Cancer Res; 2010 Nov; 16(22):5511-21. PubMed ID: 20851854
[TBL] [Abstract][Full Text] [Related]
23. Clinical significance of decreased nidogen-2 expression in the tumor tissue and serum of patients with hepatocellular carcinoma.
Cheng ZX; Huang XH; Wang Q; Chen JS; Zhang LJ; Chen XL
J Surg Oncol; 2012 Jan; 105(1):71-80. PubMed ID: 21815147
[TBL] [Abstract][Full Text] [Related]
24. Quantitative analysis of apoptosis-related gene expression in hepatocellular carcinoma.
Ikeguchi M; Hirooka Y; Kaibara N
Cancer; 2002 Nov; 95(9):1938-45. PubMed ID: 12404288
[TBL] [Abstract][Full Text] [Related]
25. Heterogeneous nuclear ribonucleoprotein A2/B1 in association with hTERT is a potential biomarker for hepatocellular carcinoma.
Mizuno H; Honda M; Shirasaki T; Yamashita T; Yamashita T; Mizukoshi E; Kaneko S
Liver Int; 2012 Aug; 32(7):1146-55. PubMed ID: 22372738
[TBL] [Abstract][Full Text] [Related]
26. Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection.
Yang XR; Xu Y; Shi GM; Fan J; Zhou J; Ji Y; Sun HC; Qiu SJ; Yu B; Gao Q; He YZ; Qin WZ; Chen RX; Yang GH; Wu B; Lu Q; Wu ZQ; Tang ZY
Clin Cancer Res; 2008 Jun; 14(12):3850-9. PubMed ID: 18559605
[TBL] [Abstract][Full Text] [Related]
27. Expression and prognostic role of Spy1 as a novel cell cycle protein in hepatocellular carcinoma.
Ke Q; Ji J; Cheng C; Zhang Y; Lu M; Wang Y; Zhang L; Li P; Cui X; Chen L; He S; Shen A
Exp Mol Pathol; 2009 Dec; 87(3):167-72. PubMed ID: 19686732
[TBL] [Abstract][Full Text] [Related]
28. Identification of cystatin B as a potential serum marker in hepatocellular carcinoma.
Lee MJ; Yu GR; Park SH; Cho BH; Ahn JS; Park HJ; Song EY; Kim DG
Clin Cancer Res; 2008 Feb; 14(4):1080-9. PubMed ID: 18281540
[TBL] [Abstract][Full Text] [Related]
29. Strong Smad4 expression correlates with poor prognosis after surgery in patients with hepatocellular carcinoma.
Hiwatashi K; Ueno S; Sakoda M; Kubo F; Tateno T; Kurahara H; Mataki Y; Maemura K; Ishigami S; Shinchi H; Natsugoe S
Ann Surg Oncol; 2009 Nov; 16(11):3176-82. PubMed ID: 19626374
[TBL] [Abstract][Full Text] [Related]
30. [Significance of glypican-3 mRNA expression in hepatocellular carcinoma tissues and peripheral blood cells].
Li BD; Zhao QC; Zhu YT; Zhang FQ; Dou KF
Zhonghua Wai Ke Za Zhi; 2006 Apr; 44(7):458-62. PubMed ID: 16772080
[TBL] [Abstract][Full Text] [Related]
31. Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma.
Daveau M; Scotte M; François A; Coulouarn C; Ros G; Tallet Y; Hiron M; Hellot MF; Salier JP
Mol Carcinog; 2003 Mar; 36(3):130-41. PubMed ID: 12619035
[TBL] [Abstract][Full Text] [Related]
32. Importin-α1 as a novel prognostic target for hepatocellular carcinoma.
Yoshitake K; Tanaka S; Mogushi K; Aihara A; Murakata A; Matsumura S; Mitsunori Y; Yasen M; Ban D; Noguchi N; Irie T; Kudo A; Nakamura N; Tanaka H; Arii S
Ann Surg Oncol; 2011 Jul; 18(7):2093-103. PubMed ID: 21286940
[TBL] [Abstract][Full Text] [Related]
33. High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma.
Yang XR; Xu Y; Yu B; Zhou J; Qiu SJ; Shi GM; Zhang BH; Wu WZ; Shi YH; Wu B; Yang GH; Ji Y; Fan J
Gut; 2010 Jul; 59(7):953-62. PubMed ID: 20442200
[TBL] [Abstract][Full Text] [Related]
34. [Overexpression and genomic amplification of decoy receptor 3 in hepatocellular carcinoma and significance thereof].
Shen HW; Wu YL; Peng SY
Zhonghua Yi Xue Za Zhi; 2003 May; 83(9):744-7. PubMed ID: 12899749
[TBL] [Abstract][Full Text] [Related]
35. [Selective deposition of agrin in the microvasculature of hepatocellular carcinoma: aspects in pathogenesis and differential diagnosis].
Tátrai P
Magy Onkol; 2008 Dec; 52(4):379-83. PubMed ID: 19068466
[TBL] [Abstract][Full Text] [Related]
36. The gene expression level of transforming growth factor-beta (TGF-beta) as a biological prognostic marker of hepatocellular carcinoma.
Ikeguchi M; Iwamoto A; Taniguchi K; Katano K; Hirooka Y
J Exp Clin Cancer Res; 2005 Sep; 24(3):415-21. PubMed ID: 16270528
[TBL] [Abstract][Full Text] [Related]
37. Combined functional genome survey of therapeutic targets for hepatocellular carcinoma.
Satow R; Shitashige M; Kanai Y; Takeshita F; Ojima H; Jigami T; Honda K; Kosuge T; Ochiya T; Hirohashi S; Yamada T
Clin Cancer Res; 2010 May; 16(9):2518-28. PubMed ID: 20388846
[TBL] [Abstract][Full Text] [Related]
38. [Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients].
Zhou Q; Liang LJ; Peng BG; Zhen YY
Ai Zheng; 2006 Nov; 25(11):1433-8. PubMed ID: 17094916
[TBL] [Abstract][Full Text] [Related]
39. Proteomic profiling reveals the prognostic value of adenomatous polyposis coli-end-binding protein 1 in hepatocellular carcinoma.
Orimo T; Ojima H; Hiraoka N; Saito S; Kosuge T; Kakisaka T; Yokoo H; Nakanishi K; Kamiyama T; Todo S; Hirohashi S; Kondo T
Hepatology; 2008 Dec; 48(6):1851-63. PubMed ID: 18937283
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathological significance of survivin expression in patients with hepatocellular carcinoma.
Chau GY; Lee AF; Tsay SH; Ke YR; Kao HL; Wong FH; Tsou AP; Chau YP
Histopathology; 2007 Aug; 51(2):204-18. PubMed ID: 17559540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
